| 15/09/21 |
Result of AGM |
| 15/09/21 |
AGM Trading Update |
| 06/09/21 |
VISITECT® COVID-19 antigen test self-test submission update |
| 30/07/21 |
Posting of AR and Accounts and Notice of AGM |
| 27/07/21 |
AbC-19 monitors vaccine response to variants |
| 13/07/21 |
Final results for year ended 31 March 2021 |
| 13/07/21 |
Directorate Change |
| 09/07/21 |
AbC-19 Rapid Antibody Test Performance Evaluation |
| 02/07/21 |
FDA Submission for Emergency Use Authorisation |
| 16/06/21 |
Notice of results - Investor presentation |
| 15/06/21 |
Statement re. Media Comment |
| 08/06/21 |
Regulatory progress for VISITECT® COVID-19 Antigen test |
| 07/06/21 |
DHSC Progress Update |
| 01/06/21 |
Positive study data for Mologic COVID-19 lateral flow antigen test |
| 05/05/21 |
Further positive data for Mologic COVID-19 lateral flow antigen test |
| 30/04/21 |
Exercise of Options and Total Voting Rights |
| 30/04/21 |
Launch of VISITECT COVID-19 Antigen & Update |
| 23/04/21 |
Exercise of Options and Total Voting Rights |
| 19/04/21 |
Director / PDMR Shareholding |
| 31/03/21 |
Exercise of Options and Total Voting Rights |
| 26/03/21 |
Exercise of Options and Total Voting Rights |
| 22/03/21 |
CE-Mark of Mologic COVID-19 lateral flow antigen test |
| 19/03/21 |
Exercise of Options and Total Voting Rights |
| 15/03/21 |
Statement re. Government press release |
| 15/03/21 |
UK Public Sector Contract disclosure |
| 08/03/21 |
Grant of Options |
| 02/03/21 |
Contract with Screen4 for COVID-19 antibody laboratory-based testing service |
| 24/02/21 |
UK-RTC statement on AbC-19TM rapid antibody test |
| 19/02/21 |
Director/PDMR Shareholding, Exercise of Options and Total Voting Rights |
| 18/02/21 |
Director/PDMR Shareholding, Exercise of Options and Total Voting Rights |
| 16/02/21 |
AbC-19TM rapid antibody test performance data |
| 15/02/21 |
Director/PDMR Shareholding, Exercise of Options and Total Voting Rights |
| 11/02/21 |
UK Government manufacturing contract. Board appointment & trading update |
| 11/02/21 |
Directorate Change |
| 08/02/21 |
Statement re. media comment |
| 02/02/21 |
Exercise of Options and Total Voting Rights |
| 28/01/21 |
Exercise of Options and Total Voting Rights |
| 26/01/21 |
Update re AbC-19TM Rapid Test & Launch of COVID-19 antibody laboratory-based testing service |
| 26/01/21 |
Launch of COVID-19 antibody laboratory-based testing service |
| 22/01/21 |
Exercise of Options and Total Voting Rights |
| 11/01/21 |
Exercise of Options and Total Voting Rights |
| 29/12/20 |
Update re AbC-19TM Rapid Test |
| 29/12/20 |
AbC-19TM Rapid Test Update |
| 24/12/20 |
Mologic CE Mark Rapid Antigen Test |
| 11/12/20 |
Exercise of Options and Total Voting Rights |
| 07/12/20 |
Exercise of Options and Total Voting Rights |
| 02/10/20 |
Director/PDMR Shareholding |
| 30/11/20 |
Exercise of Options and Total Voting Rights |
| 30/11/20 |
Interim Results - Six months ended 30 September 2020 |
| 23/11/20 |
Exercise of Options and Total Voting Rights |
| 17/11/20 |
UK-RTC Update |
| 16/11/20 |
Holding(s) in Company |
| 16/11/20 |
Holding(s) in Company |
| 13/11/20 |
Exercise of Options and Total Voting Rights |
| 12/11/20 |
UK-RTC Statement |
| 12/11/20 |
Response to media comment |
| 11/11/20 |
Investor presentation – Q&A Update |
| 09/11/20 |
Exercise of Options and Total Voting Rights |
| 06/11/20 |
Exercise of Options and Total Voting Rights |
| 03/11/20 |
Chinese approval for self-test use of Food Detective® test |
| 30/10/20 |
Exercise of Options and Total Voting Rights |
| 29/10/20 |
Notification of Major Holdings |
| 28/10/20 |
Trading update and notice of interim results |
| 20/10/20 |
Notice of Trading Update and Investor Presentation |
| 20/10/20 |
Exercise of Options and Total Voting Rights |
| 19/10/20 |
UK-RTC contract for the Supply of Goods |
| 14/10/20 |
Exercise of Options and Total Voting Rights |
| 09/10/20 |
Exercise of Options and Total Voting Rights |
| 07/10/20 |
UK Government contract for UK-RTC |
| 06/10/20 |
Notification of Major Holdings |
| 06/10/20 |
UK Government contract for UK-Rapid Test Consortium |
| 02/10/20 |
Preliminary report published by Ulster University |
| 29/09/20 |
Investor Presentation |
| 15/09/20 |
Exercise of Options and Total Voting Rights |
| 15/09/20 |
TR-1: Standard form for notification of major holdings |
| 14/09/20 |
Exercise of Options and Total Voting Rights |
| 10/09/20 |
Holding(s) in Company |
| 07/09/20 |
Statement regarding Share Price Movement |
| 07/09/20 |
Completion of self-test usability study for AbC-19™ Rapid test |
| 03/09/20 |
CE-Mark for Mologic COVID-19 antibody test |
| 01/09/20 |
Exercise of Options and Total Voting Rights |
| 26/08/20 |
Result of Annual General Meeting |
| 26/08/20 |
Exercise of Options and Total Voting Rights |
| 24/08/20 |
Exercise of Options and Total Voting Rights |
| 21/08/20 |
WHO Prequalification Received |
| 30/07/20 |
Update on progress of UK-Rapid Test Consortium |
| 24/07/20 |
Exercise of Options and Total Voting Rights |
| 23/07/20 |
Notice of AGM and posting of Annual Report |
| 20/07/20 |
Investor Presentation |
| 14/07/20 |
Final Results - Year Ended 31 March 2020 |
| 10/07/20 |
Result of General Meeting |
| 10/07/20 |
Notice of Results |
| 08/07/20 |
Result of Open Offer |
| 02/07/20 |
COVID-19 ELISA - Approval for sale in India |
| 29/06/20 |
Update on progress of UK-Rapid Test Consortium - Design Freeze |
| 22/06/20 |
Publication of Shareholder Circular |
| 22/06/20 |
Investor presentation |
| 19/06/20 |
Fundraising to raise gross proceeds of up to £11m |
| 09/06/20 |
Trading Update |
| 03/06/20 |
Update on progress of UK-Rapid Test Consortium |
| 01/06/20 |
Holdings in Company |
| 27/05/20 |
Statement regarding share price movement |
| 22/05/20 |
Exercise of Options and Total Voting Rights |
| 07/05/20 |
Exercise of Options and Total Voting Rights |
| 04/05/20 |
Exercise of Options and Total Voting Rights |
| 30/04/20 |
Exercise of Options and Total Voting Rights |
| 29/04/20 |
Holdings in Company |
| 28/04/20 |
Holdings in Company |
| 28/04/20 |
Supply Agreement with Clinton Health Access Initiative, Inc. |
| 27/04/20 |
CE-Mark of COVID-19 ELISA antibody test |
| 20/04/20 |
Material Transfer Agreement with Mologic on COVID-19 |
| 20/04/20 |
Holdings in Company |
| 16/04/20 |
Holdings in Company |
| 16/04/20 |
Holdings in Company |
| 14/04/20 |
Holdings in Company |
| 09/04/20 |
MOU on COVID-19 Consortium |
| 06/04/20 |
MSF Trial Publication |
| 06/04/20 |
Holding(s) in Company |
| 02/04/20 |
ODX Trading Update |
| 02/04/20 |
Chinese Approval for Food Detective Test |
| 24/01/20 |
Grant of Options |
| 17/01/19 |
VISITECT CD4 350 Nigeria MOH approval |
| 02/12/19 |
Interim Results - Year Ended 30 September 2019 |
| 02/12/19 |
Nigerian order for VISITECT CD4 |
| 25/11/19 |
Update on Allergy Test Menu |
| 21/11/19 |
Investor Briefing |
| 22/10/19 |
Result of AGM |
| 22/10/19 |
Trading Update and Notice of Interim Results |
| 15/10/19 |
Holding(s) in Company |
| 14/10/19 |
Holding(s) in Company |
| 14/10/19 |
Holding(s) in Company |
| 11/10/19 |
Holding(s) in Company |
| 10/10/19 |
Result of General Meeting |
| 27/09/19 |
Notice of AGM and posting of annual report |
| 23/09/19 |
Placing & Subscription and Notice of General Meeting |
| 23/09/19 |
Final Results – Year Ended 31 March 2019 |
| 16/09/19 |
Update on VISITECT® CD4 Advanced Disease test |
| 10/09/19 |
Purchase Order for Chinese Food Detective® test |
| 20/08/19 |
VISITECT CD4 Advanced Disease order |
| 16/08/19 |
Results, Trading Update & Nigerian CD4 Order |
| 06/06/19 |
Announcement of Results |
| 05/06/19 |
Holding(s) in Company |
| 03/06/19 |
Holding(s) in Company |
| 22/05/19 |
Subscription to raise c.£635,000 |
| 17/04/19 |
Trading Update |
| 18/03/19 |
CD4 Advanced Disease CE-Mark |
| 06/03/19 |
VISITECT CD4 Update |
| 01/03/19 |
Board Appointment |
| 29/01/19 |
VISITECT CD4 Advanced Disease Validation |
| 10/12/18 |
Directorate Change |
| 03/12/18 |
Interim Results - Six months ended 30 Sep 2018 |
| 19/10/18 |
Holding(s) in Company |
| 10/10/18 |
Trading Update |
| 27/09/18 |
Allersys CE Mark |
| 14/09/18 |
Result of AGM |
| 10/09/18 |
Holding(s) in Company |
| 06/06/18 |
FINAL RESULTS FOR THE YEAR ENDED 31 MARCH 2018 |
| 06/08/18 |
VISITECT® CD4 Advanced Disease Development Update |
| 18/07/18 |
VISITECT® CD4 commercialisation update |
| 02/07/18 |
Notice of Results - RNS |
| 28/06/18 |
Disposal of Infectious Disease Business |
| 21/05/18 |
VISITECT CD4 Update |
| 08/05/18 |
Allersys CE Mark |
| 02/05/18 |
Closure of Omega Diagnostics GmbH |
| 24/04/18 |
PDRM Dealing |
| 24/04/18 |
Holding(s) in Company |
| 23/04/18 |
Holding(s) in Company |
| 23/04/18 |
Director/PDMR Shareholding |
| 23/04/18 |
Holding(s) in Company |
| 23/04/18 |
Director/PDMR Shareholding |
| 20/04/18 |
Allersys Distributon Agreement |
| 10/04/18 |
Strategic Review of Operations and Trading Update |
| 10/04/18 |
Price Monitoring Extension |
| 12/01/18 |
Holding(s) in Company |
| 21/12/17 |
Allersys® CE-Mark |
| 14/12/17 |
CEO Succession |
| 29/11/17 |
VISITECT® CD4 CE-Mark |
| 01/11/17 |
Change of Registered Address |
| 23/10/17 |
Trading Update and Notice of Interim Results |
| 16/10/17 |
US Supply Agreement |
| 10/10/17 |
Holding(s) in Company |
| 05/09/17 |
Exercise of Options and Total Voting Rights |
| 29/08/17 |
Result of AGM |
| 18/07/17 |
Result of General Meeting |
| 17/07/17 |
Result of Open Offer |
| 06/07/17 |
Sale and leaseback of the building owned by Omega GmbH |
| 30/06/17 |
Result of Proposed Fundraising |